
BCYC Stock Forecast & Price Target
BCYC Analyst Ratings
Bulls say
Bicycle Therapeutics PLC is experiencing a positive outlook due to the promising Phase 1 results from its product candidate BT8009, which has increased the probability of success in key oncology indications to 40%. Additionally, the company's advanced clinical assets, BT8009 and BT5528, have demonstrated acceptable safety and efficacy in treating urothelial and ovarian cancers, potentially distinguishing them from existing therapies. Furthermore, rapid enrollment in the Duravelo-2 trials is exceeding expectations, indicating strong interest and viability in its drug development pipeline.
Bears say
Bicycle Therapeutics PLC faces a negative outlook primarily due to the uncertain future of its product candidate, BT8009, which may yield lower-than-expected Phase 1 results and a projected 0% probability of success, significantly devaluing the company’s asset base. The company has reported disappointing clinical data for its therapeutic candidates in triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC), contributing to concerns over the sales potential of its products amidst increasing competitive pressures. Additionally, elevated selling, general, and administrative (SG&A) expenses, reported at $21.6 million, exceeded both analyst estimates and consensus, underscoring financial risks associated with the company's capital-intensive development initiatives.
This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.
BCYC Analyst Forecast & Price Prediction
Start investing in BCYC
Order type
Buy in
Order amount
Est. shares
0 shares